Replies to post #148197 on Biotech Values

[biomaven0]

Could we say that the fact that there's already an approved drug on the market with the same MoA bodes well for chances of success for this BLRX drug?

Not really - they are going after an oncology indication, which is quite different from a stem cell transplant indication. Also plerixafor is a small molecule drug and this is a peptide.

Peter